Amplia Therapeutics (Amplia Therapeutics) Total Stockholders Equity : $9.48 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics Total Stockholders Equity?

Amplia Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $9.48 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Amplia Therapeutics's Book Value per Share for the quarter that ended in Sep. 2023 was $0.05. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Amplia Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2023 was 0.15.

Amplia Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Amplia Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Total Stockholders Equity Chart

Amplia Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Stockholders Equity

Get a 7-Day Free Trial

6.14

5.35

7.97

16.11

10.57

Amplia Therapeutics Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Total Stockholders Equity	Get a 7-Day Free Trial															9.23	16.11	12.70	10.57	9.48

Amplia Therapeutics (OTCPK:INNMF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Amplia Therapeutics's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(9.481	-	0)	/	199.616
	=	0.05

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Amplia Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.404	+	0.035)	/	9.481
	=	0.15

Amplia Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023